Skip to content
Politically.com Search all
Menu

2025 · 1st Quarter (Jan 1 - Mar 31)

TRAVERE THERAPEUTICS

Filed by ALSTON & BIRD LLP.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
1st Quarter - Amendment
Posted
Mar 3, 2026
Income
$60,000.00
Expenses
Not reported
Filing UUID
9629ca4a-ac2b-4c25-84ac-5bd1c36c5b83
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Support for H.R.946, Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. Legislation regarding newborn screening. H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Policies regarding copay accumulators and impact on rare disease patients. Support of reauthorization of priority review voucher program. H.R.1968, Full-Year Continuing Appropriations and Extensions Act, 2025.

Literal federal measure citations: H.R.946, H.R.1518, H.R.1968

MMM · Medicare/Medicaid

Support for H.R.946, Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation impacting products approved under the Accelerated Approval pathway. H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Policies regarding copay accumulators and impact on rare disease patients.

Literal federal measure citations: H.R.946, H.R.1518

PHA · Pharmacy

Support for H.R.946, Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation regarding orphan drug pricing, value, and reimbursement, relative to the Inflation Reduction Act of 2022 (Pub. L. No. 117-169, 136 Stat. 1818 (2022)). Policies regarding copay accumulators and impact on rare disease patients. Support of reauthorization of priority review voucher program. H.R.1968, Full-Year Continuing Appropriations and Extensions Act, 2025.

Literal federal measure citations: H.R.946, H.R.1968

MED · Medical/Disease Research/Clinical Labs

Legislation regarding clinical research for rare diseases and orphan drug development, and the Accelerated Approval pathway. Support of reauthorization of priority review voucher program.

TAX · Taxation/Internal Revenue Code

H.R.1414, Camerons Law, to restore the amount of the Orphan Drug Tax Credit. Legislation to improve education and care pathways for patients with rare kidney disease.

Literal federal measure citations: H.R.1414

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.